Brevan Howard Capital Management LP Halozyme Therapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $9.23 Billion
- Q1 2025
A detailed history of Brevan Howard Capital Management LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 15,216 shares of HALO stock, worth $794,427. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,216
Previous 20,996
27.53%
Holding current value
$794,427
Previous $1 Million
3.29%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
594Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$920 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$670 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$316 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$203 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$192 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.27B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...